secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001764013-23-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started
--------------------------------------------------------------------------------

- Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.
- Full-year net loss $211.0M ($1.71/share) vs $156.7M ($1.43); cash $376.5M funding into H2 2025.
- R&D expenses rose 61% YoY to $160.3M, driven by batoclimab and IMVT-1402 programs.
- FDA IND and MEDSAFE CTA cleared for IMVT-1402; Phase 1 trial enrolling in New Zealand.
- Initial Phase 1 data from single-ascending dose expected Aug/Sep 2023; MAD data Oct/Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/0001764013-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000063/imvt-20230522.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer